Efficacy of Intralesional Bevacizumab Versus Intralesional Triamcinolone Acetonide Injection in the Treatment of Keloids: A Randomized Clinical Trial.
Rana F Hilal, Nourhan Osama, Samar El-Tahlawi et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized clinical trial compared monthly intralesional triamcinolone acetonide (TAC) with bevacizumab over three sessions in 28 adults with post-traumatic keloids. Outcomes included the modified Vancouver Scar Scale (mVSS), erythema, histopathology, and biochemical markers. The TAC group had significantly better mVSS results than the bevacizumab group, and patient satisfaction and physician global assessment also favored TAC. TAC was associated with reduced VEGF and increased collagen type III, while bevacizumab improved collagen-fiber spacing. The abstract does not report numerical effect sizes for these comparisons.
Key findings
- The mVSS differed significantly between groups, favoring intralesional TAC.
- Patient satisfaction and physician global assessment showed superior outcomes with TAC.
- TAC treatment significantly decreased VEGF and increased collagen type III.
- Bevacizumab treatment significantly improved spacing between collagen fibers.
Why it matters
The trial provides a direct comparison of two intralesional approaches for post-traumatic keloids and reports better overall clinical assessments with TAC. Its biomarker and histopathological findings also suggest differing tissue responses to the treatments. These results help frame bevacizumab as an investigational option rather than an established alternative based on this study.
What to keep in mind
The trial included 28 adults and assessed outcomes after three treatment sessions; the abstract provides no numerical effect estimates or longer-term follow-up results.